First test of VX-433 in people for narcolepsy type 1
Tests the safety of VX-433 for narcolepsy type 1.
Key facts
- Who runs it
- Vertex Pharmaceuticals Incorporated
- Where
- Salt Lake City, United StatesSee the site
- Trial code
- Registry title
- A Phase 1, First-in-human Study of VX-433
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 118 people, planned
- Started
- 21 May 2026
- Expected to end
- 5 Mar 2027
- Type of study
- Interventional, 5 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- VX-433
- Placebo
- Midazolam
- Bupropion
- Record updated
- 8 June 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults to test the safety of a new drug, VX-433, and how the body handles it. It also checks how VX-433 changes the way the body handles midazolam and bupropion. The record says healthy volunteers can join.
- Age
- 18 Years to 55 Years
- Sex
- All sexes can join.
- Biomarker or test result
- Body mass index (BMI) of 18.0 to 30.0 kg/m2. Body weight of more than 50 kg (110 lb). Nonsmoker, or stopped smoking at least 3 months before screening, confirmed by a urine or blood cotinine test.
Main reasons for not taking part
- A fever or other short-term illness not fully gone within 14 days before the first dose
- Any condition that may affect how the body takes up the drug
- Women who can become pregnant
- Pregnant or breastfeeding women, or women planning pregnancy or egg donation during the study or within 90 days after the last dose
- Other rules set by the protocol also apply
The registry criteria, word for word
Show all 6 criteriaShow less
Who can take part
- Body mass index (BMI) of 18.0 to 30.0 kilogram per meter square (kg/m2), inclusive
- A total body weight of more than (>) 50 kg
- Nonsmoker or ex-smoker for at least 3 months before screening with current nonsmoking status confirmed by urine or blood cotinine at screening
Who cannot take part
- History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
- For female participants: of childbearing potential, pregnant, breastfeeding, or planning to become pregnant or donate ova during the study or within 90 days after last dose of study drug; Other protocol defined Inclusion/Exclusion criteria will apply
- Any condition possibly affecting drug absorption
Check if you might fit
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 55 years old?
Where in United States
- ICON - Utah - Salt Lake City OfficeSalt Lake City, United StatesTaking people
About the trial
What the trial wants to find out
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of VX-433 following single and multiple ascending doses, as well as to assess the effect of VX-433 on the PK of midazolam, bupropion, and hydroxybupropion.
The 5 groups in the trial
- Part A: Single Ascending Dose (SAD)Treatment being tested
Participants will be randomized to receive a single dose of VX-433.
Treatment: VX-433
- Part A: PlaceboPlacebo, for comparison
Participants will be randomized to receive placebo matched to VX-433.
Treatment: Placebo
- Part B: Multiple Ascending Dose (MAD)Treatment being tested
Participants will be randomized to receive multiple doses of VX-433.
Treatment: VX-433
- Part B: PlaceboPlacebo, for comparison
Participants will be randomized to receive placebo matched to VX-433.
Treatment: Placebo
- Part C: Drug Drug InteractionTreatment being tested
Participants will receive a single dose of midazolam and bupropion on Day 1 in Dosing Period 1, followed by VX-433 administration for 17 days (Days 5 through 21) and then midazolam and bupropion on Day 18 in Dosing Period 2. Part C will be open-label.
Treatment: VX-433, Midazolam, and Bupropion
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorSaves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase 1, First-in-human Study Evaluating the Safety, Tolerability, and Pharmacokinetics of VX-433 and Its Effects on the Pharmacokinetics of Midazolam and Bupropion
- Plain-language title
- First test of VX-433 in people for narcolepsy type 1Generated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Fit questions
- Built from NCT07584434, who can take part
- Record updated
- 8 June 2026